Modra is applying its proprietary technology to transform
standard taxane therapies
Better tolerated taxane therapies, taken as pills at home
Intravenous (IV) taxane therapy is a globally recognized cornerstone of cancer treatment. Despite its widespread use and status as a critical component of standard-of-care for many solid tumors, the taxane class of anti-cancer therapy is also hampered by its severe side effects and high burden IV administration schedule. There remains considerable potential to improve the lives of hundreds of thousands of cancer patients and reduce the strain taxane therapy places on them and global healthcare systems.
“Modra” stands for “Modulated Oral Drug Absorption” and for our commitment to transforming taxane therapy, by developing improved therapies that are safer, better tolerated, and can be conveniently taken at home in tablet form. We are applying our proprietary platform to develop next-generation oral taxanes with the goal to improve the therapeutic outcomes and everyday lives of cancer patients undergoing taxane therapy.
OUR LEAD PROGRAM
Our lead program, ModraDoc006/r, a boosted oral formulation of docetaxel, is currently being evaluated in a Phase 2b clinical study in metastatic Castration-Resistant Prostate Cancer (mCRPC) cancer patients.
Modra was founded in June 2010 as a spin-out of the Netherland’s Cancer Institute (Nederlands Kanker Instituut Antoni van Leeuwenhoek) and MC Slotervaart Hospital in Amsterdam, and is based in Amsterdam, the Netherlands.
Our Management Team
Modra’s team comprises of the technical expertise and deep industry experience that enables the company both to formulate and execute on its strategy efficiently and effectively.
Modra’s Supervisory Board consists of individuals with a deep history and appreciation for our approach, as well as the key expertise both to challenge and support us as we move forward.